Remove Allergies Remove Generic Pharmaceutical Remove Marketing
article thumbnail

Jubilant Pharma Ltd. and Aavis Pharmaceuticals launch Hydroxychloroquine Sulfate tablets in the U.S. market

The Pharma Data

and Aavis Pharmaceuticals Inc. “We are pleased to announce the commercial launch of Hydroxychloroquine Sulfate tablets in the U.S.through our marketing partner,” stated Ashok Barot , Chairman, Aavis Pharmaceuticals. D/B/A Aavis Pharmaceuticals. About Jubilant Cadista Pharmaceuticals Inc. YARDLEY, Pa.

article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

We delve into the driving forces behind their successes and shed light on the groundbreaking research that has earned them a place among the elite in the pharmaceutical arena. is a global pharmaceutical company, working across both developed and emerging markets. 2022 Revenue: Pfizer reported an annual revenue of $100.33

Sales 90
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

COVAXX and Aurobindo Pharma Announce COVID-19 Vaccine Partnership

The Pharma Data

COVAXX is committed to providing an equitable distribution of UB-612 vaccine by prioritizing markets where the unmet need is greatest,” said Mei Mei Hu, co-founder and CEO of COVAXX. Aurobindo Pharma and COVAXX are partnering on clinical development, manufacturing and marketing of COVAXX’s vaccine candidate, UB-612.

article thumbnail

Aurobindo Pharma and COVAXX Sign an Exclusive Agreement to Develop and Commercialize COVID-19 Vaccine UB-612 for India and UNICEF

The Pharma Data

. Under the signed agreement, Aurobindo Pharma has obtained the exclusive rights to develop, manufacture and sell COVAXX’s UB-612 vaccine in India and to UNICEF, as well as non-exclusive rights in other select emerging and developing markets. The Company is marketing these products globally, in over 150 countries.